Redeye retains its positive view of Avensia despite a soft Q2, with sales and EBIT below our expectations. Although Q2 was hurt by low utilization, Avensia experienced a gradual improvement during the quarter thanks to personnel reductions and a stabilized market. While we somewhat cut our forecast and Base Case, we still expect significant margin improvements mid-term, and we believe the case is intact.

Read more and download the Research Update.

Follow companies at Redeye to receive the latest equity research within Life Science and Technology.

This is a press release from Redeye - Research Powered Investment Banking. www.redeye.se/

Attachments

Avensia - Positive Trend in Utilization Rates

© Modular Finance, source Nordic Press Releases